#China #FDA Approval #Chengdu #copper-64 #C-Ray Therapeutics

C-Ray Therapeutics Announces FDA Acceptance of Cu-64 DMF

C-Ray Therapeutics (Chengdu) Co., Ltd. has made headlines with the announcement of its Type II Drug Master File (DMF) acceptance by the U.S. Food and Drug Administration (FDA) for Copper-64 (Cu-64) chloride, a critical component for radiolabeling purposes. Officially registered under DMF No. 43568, this development is a significant step for the company and the radiopharmaceutical industry at large.

Understanding Copper-64: A Step Forward in Diagnostics

Copper-64 offers a distinctive half-life of about 12.7 hours, considerably longer than currently available radionuclides like Gallium-68 (Ga-68) and Fluorine-18 (F-18). This characteristic not only facilitates substantial large-scale production but allows for storage durations of up to 48 hours. With these advancements, healthcare providers experience less scheduling pressure at imaging facilities, ensuring improved and timely access to Positron Emission Tomography (PET) diagnostics for patients.

Clinical research underscores the effectiveness of Cu-64; a recent study highlighted in European Urology showcased the superiority of Cu-64 SAR-bisPSMA (Co-PSMA) in detecting prostate cancer lesions compared to its Ga-68 counterpart. The results revealed that patients with Cu-64 imaging agents had over twice the number of identifiable lesions, with a detection rate soaring to 78% compared to just 36% for Ga-68 PSMA-11, showcasing the potential of Cu-64 in oncological applications.

Innovative Manufacturing Techniques

C-Ray Therapeutics has tackled significant technical challenges successfully through its proprietary production method and an automated facility designed explicitly for this purpose. Utilizing an advanced Ni-64 recycling process with an impressive recovery rate of up to 90%, the company ensures that high-grade Ni-64 can be reused, fostering sustainable operations that are both economically and environmentally viable. With a batch capacity that exceeds 2 Ci at the end of bombardment (EOB), C-Ray presents a formidable manufacturing option within the industry.

Additionally, C-Ray offers comprehensive services that include radiolabeling, formulation, fill-finish, and cold-chain logistics. This array of end-to-end solutions positions the company as a valuable partner for radiopharmaceutical manufacturers.

Goals for the Future

According to Qiao Haitao, General Manager of C-Ray Therapeutics, the FDA acceptance of the Cu-64 DMF signifies a key milestone. It articulates C-Ray's commitment to high manufacturing standards, and positions the company as a reliable partner in the field of diagnostics. By alleviating compliance burdens on domestic biopharma as they seek to develop Cu-64-based agents, this development additionally bolsters the credibility of the company's factories amidst global competitors.

For international organizations focusing on radiopharmaceutical developments, the establishment of a dependable Cu-64 supply source from China facilitates clinical advancement and regulatory strategies. Moving forward, C-Ray Therapeutics plans to further enhance its service capabilities and forge collaborations on a global scale, ultimately aiming to increase patient access to advanced nuclear medicine.

About C-Ray Therapeutics

C-Ray Therapeutics stands out as a global Contract Research, Development, and Manufacturing Organization (CRDMO) dedicated to the development of radiopharmaceuticals. With a modern facility in Chengdu covering 28,000 square meters and authorized under China's Class A Radiation Safety License, the company boasts expertise in over 30 radioisotopes and has successfully completed more than 100 projects across various medicinal applications, indicating its leadership in the global radiopharmaceutical landscape. For more information, visit C-Ray Therapeutics.